Arnatar Therapeutics develops nucleic acid medications using antisense oligonucleotide (ASO) and small interfering RNA (siRNA) technologies to target and modulate dysfunctional RNA associated with various diseases. The company aims to create personalized therapies for patients with unmet medical needs by addressing the underlying causes of RNA-related disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are caused by mutations or abnormal expression of RNA. Current treatment options often fail to address the underlying RNA dysfunction, leaving unmet medical needs for patients with RNA-related disorders.
Solution
Arnatar Therapeutics develops personalized nucleic acid medications using antisense oligonucleotide (ASO) and small interfering RNA (siRNA) technologies. These therapies are designed to specifically target and modulate dysfunctional RNA associated with various diseases, addressing the root cause of the condition. By targeting RNA, Arnatar aims to create rationally designed medicines tailored to individual patients, offering a novel approach to treating both large and rare disease indications. The company leverages cutting-edge antisense technology to discover and develop next-generation medicines.
Target Audience
The primary target audience includes patients with unmet medical needs related to RNA-related disorders, as well as healthcare providers seeking personalized and targeted therapeutic options.
Features
- Utilizes antisense oligonucleotide (ASO) technology for targeted RNA modulation.
- Employs small interfering RNA (siRNA) technology for gene silencing.
- Designs personalized medicines based on individual patient RNA profiles.
- Focuses on addressing the underlying causes of RNA-related disorders.
- Develops therapies for both large and rare disease indications.